Citations

Mayo Clinic

Clear

952 citation(s) found for "Ta, Monica".

Pilot study of women’s perspectives when abnormal uterine bleeding occurs during perimenopause
DeStephano, Christopher C. , Allyse, Megan , Ridgeway, Jennifer L. , Salinas, Mónica, Spaulding, Aaron , DeStephano, C C , Ridgeway, Jennifer L , Spaulding, Aaron , Allyse, Megan A , Dabrh, Abd Moain Abu , Salinas, M., Sherman, Mark E.

Climacteric | June 2, 2022 | Volume: 25 | Issue: 5 | Pages: 510-515

10.1080/13697137.2022.2073810 | PMID 35652469 Get It

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
Gardea-Resendez, Manuel, Taylor-Desir, Monica J., Romo-Nava, Francisco, Bond, David, Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Ozerdem, Aysegul, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A., Singh, Balwinder , Bond, David J. , Özerdem, Ayşegül , Romo‐Nava, Francisco , Gardea‐Resendez, Manuel , Romo-Nava, F , Bond, David J , Singh, Balwinder , Ozerdem, Aysegul , Gardea-Resendez, Manuel , Taylor-Desir, Monica J., Vallender, Eric J., Cuellar-Barboza, Alfredo B., Prieto, Miguel L., Nunez, Nicolas, Veldic, Marin, Singh, Balwinder, Markota, Matej, Colby, Colin L., Coombes, Brandon J., Biernacka, Joanna M., McElroy, Susan L., Frye, Mark A.

Journal of Clinical Psychopharmacology | May 31, 2022 | Volume: 42 | Issue: 2 | Pages: 159-162

10.1097/jcp.0000000000001532 | PMID 35230047 Get It

Abstract Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD− group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.
In Response
McMullen, Kaley, Harbell, Monica W. , Kraus, Molly B.

Anesthesia & Analgesia | May 20, 2022 | Volume: 134 | Issue: 6 | Pages: e39-e40

10.1213/ane.0000000000005997 | PMID 35595704 Get It

Advances in Primary Progressive Aphasia
Matías‐Guiu, Jordi A. , Lavoie, Monica , Utianski, Rene L. , Lavoie, Monica , Utianski, Rene L , Laforce, Robert

Brain Sciences | May 12, 2022 | Volume: 12 | Issue: 5 | Pages: 636

10.3390/brainsci12050636 | PMID 35625022 Get It

Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by progressive and predominant language impairment [...]
Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial
Harding, James J. , Shah, Ronak , Murphy, Jessica, Cleary, James M. , Shapiro, Geoffrey I. , Moreno, Víctor , Loi, Sherene , Spanggaard, Iben , Park, Haeseong , Stemmer, Salomon M. , DiPrimeo, Daniel, Savin, Casey , Selçuklu, S. Duygu , Berger, Michael , Moreno, Victor , Loi, Sherene , Shapiro, Geoffrey I , Harding, James J , Piha‐Paul, Sarina A. , Quinn, David I , Braña, Irene , Borad, Mitesh J. , Ford, James M. , Arnedos, Mónica , Fouchardière, Christelle de la , Fountzilas, Christos , Zhang, Jie , Eli, Lisa D. , Meric‐Bernstam, Funda , Jhaveri, Komal , Solit, David B. , Abou‐Alfa, Ghassan K.

No container title available | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1576467/v1 Get It

Abstract HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid tumours harbouring oncogenic HER2 somatic mutations (NCT01953926). The primary objective of the BTC cohort was objective response rate (ORR). Among 25 treatment-refractory patients (11 cholangiocarcinoma, 10 gallbladder, 4 ampullary cancers), the ORR was 16%. The most common HER2 mutations were S310F (n = 11; 48%) and V777L (n = 4; 17%). Outcomes appeared worse for ampullary tumours or those with co-occurring oncogenic TP53 and CDKN2A alterations. Loss of amplified HER2 S310F and acquisition of multiple previously undetected oncogenic co-mutations were identified at progression in one responder. Neratinib demonstrated anti-tumour activity in patients with refractory BTC harbouring HER2 mutations. Future studies of rational combinations are warranted.
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
Broder, Joshua , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Freiermuth, Caroline E. , Griffey, Richard T. , Hooker, Edmond A. , Jang, Timothy , Meltzer, Andrew C. , Pepper, Joan D., Prakken, Steven, Upadhye, Suneel , Broder, Joshua S , Oliveira J E Silva, Lucas , Hooker, Edmond , Jang, Timothy B , Mills, Angela M , Repplinger, Michael D , Upadhye, Suneel , Carpenter, Christopher R , Bellolio, M Fernanda , Griffey, Richard T , Meltzer, Andrew C , Mills, Angela M. , Carpenter, Christopher R.

Academic Emergency Medicine | May 11, 2022 | Volume: 29 | Issue: 5 | Pages: 526-560

10.1111/acem.14495 | PMID 35543712 Get It

AbstractThis second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARYThe GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
A Bundle of the Top 10 OPAT Publications in 2021
Rivera, Christina G. , Beieler, Alison M , Childs‐Kean, Lindsey M. , Cortés-Penfield, Nicolás , Idusuyi, Ann-Marie, Keller, Sara C. , Rajapakse, Nipunie , Ryan, Keenan , Yoke, Leah H , Mahoney, Monica V. , Rajapakse, Nipunie S , Ryan, Keenan L , Rivera, Christina G , Mahoney, Monica V , Keller, Sara C

Open Forum Infectious Diseases | May 9, 2022 | Volume: 9 | Issue: 7 | Pages: No page available

10.1093/ofid/ofac242 | PMID 35855003 Get It

Abstract As outpatient parenteral antimicrobial therapy (OPAT) becomes more common, it may be difficult to stay current with recent related publications. A group of multidisciplinary OPAT clinicians reviewed and ranked all OPAT publications published in 2021. This article provides a high-level summary of the OPAT manuscripts that were voted the “top 10” publications of 2021.
Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services
Ramsey, Glenn , Park, Yara A. , Eder, Anne F. , Bobr, Aleh , Karafin, Matthew S. , King, Karen E., Schwartz, Joseph, Szczepiorkowski, Zbigniew M. , Souers, Rhona J., Thomas, Lamont, Delaney, Meghan , Karp, Julie Katz , Pagano, Monica B.

Archives of Pathology & Laboratory Medicine | April 29, 2022 | Volume: 147 | Issue: 1 | Pages: 71-78

10.5858/arpa.2021-0250-cp | PMID 35486492 Get It

Context.— Modern RHD genotyping can be used to determine when patients with serologic weak D phenotypes have RHD gene variants at risk for anti-D alloimmunization. However, serologic testing, RhD interpretations, and laboratory management of these patients are quite variable. Objective.— To obtain interlaboratory comparisons of serologic testing, RhD interpretations, Rh immune globulin (RhIG) management, fetomaternal hemorrhage testing, and RHD genotyping for weak D-reactive specimens. Design.— We devised an educational exercise in which 81 transfusion services supporting obstetrics performed tube-method RhD typing on 2 unknown red blood cell challenge specimens identified as (1) maternal and (2) newborn. Both specimens were from the same weak D-reactive donor. The exercise revealed how participants responded to these different clinical situations. Results.— Of reporting laboratories, 14% (11 of 80) obtained discrepant immediate-spin reactions on the 2 specimens. Nine different reporting terms were used to interpret weak D-reactive maternal RhD types to obstetricians. In laboratories obtaining negative maternal immediate-spin reactions, 28% (16 of 57) performed unwarranted antiglobulin testing, sometimes leading to recommendations against giving RhIG. To screen for excess fetomaternal hemorrhage after a weak D-reactive newborn, 47% (34 of 73) of reporting laboratories would have employed a contraindicated fetal rosette test, risking false-negative results and inadequate RhIG coverage. Sixty percent (44 of 73) of laboratories would obtain RHD genotyping in some or all cases. Conclusions.— For obstetric and neonatal patients with serologic weak D phenotypes, we found several critical problems in transfusion service laboratory practices. We provide recommendations for appropriate testing, consistent immunohematologic terminology, and RHD genotype–guided management of Rh immune globulin therapy and RBC transfusions.
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
Agarwal, Neeraj , Tangen, Catherine M. , Hussain, Maha , Gupta, Shilpa , Plets, Melissa , Lara, Primo N. , Harzstark, Andrea, Twardowski, Przemyslaw, Paller, Channing J. , Zylla, Dylan M. , Zibelman, Matthew R. , Levine, Ellis , Roth, Bruce J. , Goldkorn, Amir , Vaena, Daniel A. , Crispino, Tony, Thompson, Ian M. , Hussain, Maha H A , Zylla, Dylan , Kohli, Manish , Vogelzang, Nicholas J , Quinn, David I , Agarwal, Archana M , Paller, Channing J , Tangen, Catherine M , Thompson, Ian M , Kohli, Manish , Vogelzang, Nicholas J.

Journal of Clinical Oncology | April 21, 2022 | Volume: 40 | Issue: 28 | Pages: 3301-3309

10.1200/jco.21.02517 | PMID 35446628 Get It

PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. METHODS In this open-label randomized phase III study, patients with metastatic hormone-sensitive prostate cancer were randomly assigned 1:1 to ADT with orteronel (300 mg oral twice daily; experimental arm) or ADT with bicalutamide (50 mg oral once daily; control arm). The primary objective was the comparison of overall survival (OS), targeting a 33% improvement in median survival. A stratified log-rank test with a one-sided P ≤ .022 would indicate statistical significance. Secondary end points were progression-free survival (PFS), prostate-specific antigen (PSA) level at 7 months (≤ 0.2 v 0.2 to ≤ 4 v > 4 ng/mL), and adverse event profile. RESULTS Among 1,279 patients included in the analysis, 638 were randomly assigned to the ADT plus orteronel arm and 641 to the control arm. The median age was 68 years; 49% had extensive disease. After a median follow-up of 4.9 years, there was a significant improvement in PFS (median 47.6 v 23.0 months, hazard ratio 0.58; 95% CI, 0.51 to 0.67; P < .0001) and PSA response at 7 months ( P < .0001), but not in OS (median 81.1 v 70.2 months, hazard ratio 0.86; 95% CI, 0.72 to 1.02; P = .040, one-sided). More grade 3/4 adverse events occurred in the experimental versus the control arms (43% v 14%). Postprotocol life-prolonging therapy was received by 77.4% of patients in the control arm and 61.3% of patients in the orteronel arm. CONCLUSION The study did not meet the primary end point of improved OS with orteronel. The lack of correlation of PFS and PSA response with OS raises concerns over assumption of their consistent surrogacy for OS in the context of extensive postprotocol therapy in this setting.
A prescription for an outpatient parenteral antimicrobial therapy ( OPAT ) rotation for pharmacy residents
Alexander, Bryan , Rivera, Christina G. , Childs‐Kean, Lindsey M. , Rivera, Christina G , Mahoney, Monica V. , Ryan, Keenan

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 19, 2022 | Volume: 4 | Issue: 2 | Pages: 234-244

10.1002/jac5.1377 Get It

Abstract Background Outpatient parenteral antimicrobial therapy (OPAT) is an emerging area for pharmacist involvement. However, many residency training programs do not offer OPAT rotation opportunities for their residents. Objective To provide a blueprint for residency programs hoping to offer OPAT rotations for postgraduate year 1 (PGY1) or postgraduate year 2 (PGY2) pharmacy residents. Results As a rotation area with copious patient interaction, there are many unique accreditation objectives that can be taught and evaluated in an OPAT rotation. The OPAT rotation format may be longitudinal or block. Activities the resident can complete include predischarge evaluation, patient counseling, medication selection, physical examinations, laboratory monitoring, patient presentations, documentation, projects, and educational presentations. Conclusion OPAT rotations provide many opportunities for residents to satisfy the objectives required in residency training.